A double bass player in the Atlanta Symphony Orchestra, Doug Sommer claims he was just “in the right place at the right time with the right doctors,” when he was offered the opportunity to be the first in the state to receive a new treatment option for his prostate cancer.
Doug is the first patient in Georgia to receive a new FDA-approved radioactive therapeutic drug for advanced metastatic prostate cancer. He received the treatment, a single injection of radium Ra 223 dichloride, (brand name Xofigo) at Saint Joseph’s Hospital. This was the first of six injections. Xofigo has been shown to reduce bone pain and improve quality of life.
“Patients with a type of cancer called castration-resistant prostate cancer (CRPC) with metastatic bone disease, who have failed hormone suppression therapy, now have a new treatment option for their disease.”
– Peter Rossi, MD, medical director of radiation oncology at Saint Joseph’s Hospital and assistant professor of radiation oncology at Emory University School of Medicine & Winship Cancer Institute
Tags: new prostate cancer medication, new prostate cancer treatment, prostate cancer, prostate cancer research, prostate cancer treatment, prostate cancer treatments, treatment for prostate cancer, winship cancer institute, xofigo